Similar articles for PMID: 23796938

Year	Number of Results
1999	1
2000	3
2001	2
2002	4
2003	3
2004	4
2005	4
2006	3
2007	11
2008	6
2009	9
2010	10
2011	7
2012	5
2013	7
2014	2
2015	4
2016	7
2018	4
2019	4
2020	2
2021	1
2024	0

1

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1.

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW. Varghese V, et al. Antimicrob Agents Chemother. 2013 Sep;57(9):4290-4299. doi: 10.1128/AAC.00614-13. Epub 2013 Jun 24. Antimicrob Agents Chemother. 2013. PMID: 23796938 Free PMC article.

2

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D. Bethell R, et al. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23. AIDS Res Hum Retroviruses. 2012. PMID: 22098079

3

Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.

Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S. Taura M, et al. Free Radic Biol Med. 2013 Dec;65:778-788. doi: 10.1016/j.freeradbiomed.2013.08.161. Epub 2013 Aug 20. Free Radic Biol Med. 2013. PMID: 23973637

4

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.

Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. Dierynck I, et al. J Virol. 2007 Dec;81(24):13845-51. doi: 10.1128/JVI.01184-07. Epub 2007 Oct 10. J Virol. 2007. PMID: 17928344 Free PMC article.

5

Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.

Aoki M, Das D, Hayashi H, Aoki-Ogata H, Takamatsu Y, Ghosh AK, Mitsuya H. Aoki M, et al. mBio. 2018 Mar 6;9(2):e02425-17. doi: 10.1128/mBio.02425-17. mBio. 2018. PMID: 29511083 Free PMC article.

6

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. Dierynck I, et al. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896904 Free PMC article.

7

GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H. Amano M, et al. Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12. Antimicrob Agents Chemother. 2013. PMID: 23403426 Free PMC article.

8

GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.

Delino NS, Aoki M, Hayashi H, Hattori SI, Chang SB, Takamatsu Y, Martyr CD, Das D, Ghosh AK, Mitsuya H. Delino NS, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02060-17. doi: 10.1128/AAC.02060-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463535 Free PMC article.

9

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Luna B, Townsend MU. Luna B, et al. Clin Ther. 2007 Nov;29(11):2309-18. doi: 10.1016/j.clinthera.2007.11.007. Clin Ther. 2007. PMID: 18158073 Review.

10

C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.

Aoki M, Hayashi H, Yedidi RS, Martyr CD, Takamatsu Y, Aoki-Ogata H, Nakamura T, Nakata H, Das D, Yamagata Y, Ghosh AK, Mitsuya H. Aoki M, et al. J Virol. 2015 Nov 18;90(5):2180-94. doi: 10.1128/JVI.01829-15. J Virol. 2015. PMID: 26581995 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year